Patents by Inventor Wayne C. Drevets

Wayne C. Drevets has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250134859
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Application
    Filed: November 25, 2024
    Publication date: May 1, 2025
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Publication number: 20250090482
    Abstract: The disclosure provides methods for treating depression comprising intranasally administering to a patient in need thereof an effective amount of esketamine, wherein the patient is identified as biomarker signature positive, and wherein the patient is identified as biomarker signature positive if a biological sample obtained from the patient is identified as having a level of at least one biomarker that is greater or less than a reference biomarker level.
    Type: Application
    Filed: January 9, 2023
    Publication date: March 20, 2025
    Inventors: Wayne C. DREVETS, Hartmuth Christian KOLB, Ziad Serhal SAAD
  • Publication number: 20250064779
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient, wherein the patient is identified as biomarker signature positive. The methods comprise administering to the patient in need thereof an effective amount of an antidepressant.
    Type: Application
    Filed: January 9, 2023
    Publication date: February 27, 2025
    Inventors: Wayne C. DREVETS, Hartmuth Christian KOLB, Ziad Serhal SAAD
  • Patent number: 12201610
    Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.
    Type: Grant
    Filed: March 27, 2024
    Date of Patent: January 21, 2025
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Nicolaas Martha Felix Goyvaerts, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic, Mahesh N. Samtani, Tom Huybrechts, Geert Van der Avoort, Matthieu Ravelingien, Laura Martinez Marcos, Tatiana Marcozzi, Katarina Jokicevic
  • Patent number: 12201634
    Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: January 21, 2025
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter De Boer, Justine M. Kent, Wayne C. Drevets
  • Patent number: 12171743
    Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.
    Type: Grant
    Filed: May 31, 2024
    Date of Patent: December 24, 2024
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Patent number: 12161622
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: December 10, 2024
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Patent number: 12150929
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Grant
    Filed: January 31, 2024
    Date of Patent: November 26, 2024
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Publication number: 20240316003
    Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.
    Type: Application
    Filed: May 31, 2024
    Publication date: September 26, 2024
    Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Publication number: 20240269110
    Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.
    Type: Application
    Filed: March 27, 2024
    Publication date: August 15, 2024
    Inventors: Nicolaas Martha Felix Goyvaerts, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic, Mahesh N. Samtani, Tom Huybrechts, Geert Van der Avoort, Matthieu Ravelingien, Laura Martinez Marcos, Tatiana Marcozzi, Katarina Jokicevic
  • Publication number: 20240238245
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 18, 2024
    Inventors: Mark SCHMIDT, Vanina POPOVA, Adam SAVITZ, Rama MELKOTE, Wayne C. DREVETS, Srihari GOPAL, Darrel PEMBERTON, Chakradhar LAGISHETTY, Iva KEZIC
  • Publication number: 20240189274
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Application
    Filed: January 31, 2024
    Publication date: June 13, 2024
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Patent number: 11998525
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: June 4, 2024
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Patent number: 11998524
    Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: June 4, 2024
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Publication number: 20230348377
    Abstract: The disclosure provides compositions containing pure aticaprant, solvates of aticaprant, and methods of treating major depressive disorder using aticaprant.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 2, 2023
    Inventors: Riccardo Surmont, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Publication number: 20230277500
    Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 7, 2023
    Inventors: Nicolaas Martha Felix Goyvaerts, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic, Mahesh N. Samtani, Tom Huybrechts, Geert Van der Avoort, Matthieu Ravelingien, Laura Martinez Marcos, Tatiana Marcozzi, Katarina Jokicevic
  • Publication number: 20230277499
    Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 7, 2023
    Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Publication number: 20230233525
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 27, 2023
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Publication number: 20230089113
    Abstract: The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).
    Type: Application
    Filed: April 22, 2022
    Publication date: March 23, 2023
    Inventors: Lodewijk Ivo Caers, Jaskaran Singh, Peter Nicholas Zannikos, Wayne C. Drevets, Ella Daly, Carla Maria Canuso, Margaret Fedgchin, Frank Wiegand, Giacomo Salvadore
  • Publication number: 20220370409
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Application
    Filed: February 11, 2022
    Publication date: November 24, 2022
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic